HROW

Company Overview — What Does HARROW, INC. Do?

Harrow Health, Inc. operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business; and DEXYCU for the treatment of post-operative inflammation. The company also holds equity interests in Surface Ophthalmics, Inc., a clinical-stage pharmaceutical company that focuses on development and commercialization of therapeutics for ocular surface diseases; Melt Pharmaceuticals, Inc., a clinical-stage pharmaceutical company that focused on the development and commercialization of proprietary non-intravenous, sedation, and anesthesia therapeutics for human medical procedures in hospital, outpatient, and in-office settings; and Eton Pharmaceuticals, Inc., a commercial-stage pharmaceutical company that engages in developing and commercializing drug products. Harrow Health, Inc. owns royalty rights in four clinical stage drug candidates being developed by Surface Ophthalmics, Inc. and Melt Pharmaceuticals, Inc. The company was formerly known as Imprimis Pharmaceuticals, Inc. and changed its name to Harrow Health, Inc. in December 2018. Harrow Health, Inc. was incorporated in 2006 and is headquartered in San Diego, California. HARROW, INC. (HROW) is classified as a small-cap stock in the Healthcare sector, specifically within the Pharmaceutical Products industry. The company is led by CEO Mark L. Baum and employs approximately 180 people, headquartered in SAN DIEGO, Tennessee. With a market capitalization of $1.3B, HROW is one of the notable companies in the Healthcare sector.

HARROW, INC. (HROW) Stock Rating — Reduce (April 2026)

As of April 2026, HARROW, INC. receives a Reduce rating with a composite score of 44.1/100 and 2 out of 5 stars from the Blank Capital Research quantitative model.HROW ranks #3,341 out of 4,446 stocks in our coverage universe. Within the Healthcare sector, HARROW, INC. ranks #507 of 838 stocks, placing it in the lower half of its Healthcare peers. The rating is generated by a multi-factor model that weighs quality (30%), momentum (25%), value (15%), investment (10%), stability (10%), and short interest (10%).

HROW Stock Price and 52-Week Range

HARROW, INC. (HROW) currently trades at $36.49. The stock lost $0.80 (2.1%) in the most recent trading session. The 52-week high for HROW is $54.85, which means the stock is currently trading -33.5% from its annual peak. The 52-week low is $20.85, putting the stock 75.0% above its annual trough. Recent trading volume was 154K shares, suggesting relatively thin trading activity.

Is HROW Overvalued or Undervalued? — Valuation Analysis

HARROW, INC. (HROW) carries a value factor score of 45/100 in the Blank Capital model, indicating fair valuation relative to historical norms. The trailing price-to-earnings ratio is 1185.33x, compared to the Healthcare sector average of 23.63x — a premium of 4916%. The price-to-book ratio stands at 25.32x, versus the sector average of 2.75x. The price-to-sales ratio is 5.67x, compared to 1.66x for the average Healthcare stock. On an enterprise value basis, HROW trades at 86.24x EV/EBITDA, versus 6.34x for the sector.

Overall, HROW's valuation appears roughly in line with sector benchmarks, suggesting the market is pricing the stock fairly given its current fundamentals and growth trajectory. Neither deep value nor significantly overpriced, the stock occupies a middle ground on valuation.

HARROW, INC. Profitability — ROE, Margins, and Quality Score

HARROW, INC. (HROW) earns a quality factor score of 50/100, indicating solid business quality with consistent operational execution. The return on equity (ROE) is -30.7%, compared to the Healthcare sector average of -43.5%, which is below typical expectations for high-quality companies. Return on assets (ROA) comes in at -4.0% versus the sector average of -33.1%.

On a margin basis, HARROW, INC. reports gross margins of 73.2%, compared to 71.5% for the sector. The operating margin is 4.4% (sector: -66.1%). Net profit margin stands at -9.1%, versus -58.7% for the average Healthcare stock. Revenue growth is running at 46.4% on a trailing basis, compared to 10.6% for the sector. The overall profitability profile is adequate, though there may be room for margin expansion.

HROW Debt, Balance Sheet, and Financial Health

HARROW, INC. has a debt-to-equity ratio of 480.0%, compared to the Healthcare sector average of 32.0%. This elevated leverage warrants close monitoring, as it increases the company's sensitivity to rising interest rates and economic downturns. The current ratio is 2.20x, indicating strong short-term liquidity. Total debt on the balance sheet is $250M. Cash and equivalents stand at $74M.

HROW has a beta of 1.59, meaning it is more volatile than the broader market — a $10,000 investment in HROW would be expected to move 58.8% more than the S&P 500 on any given day. The stability factor score for HARROW, INC. is 36/100, suggesting elevated price swings that may be unsuitable for conservative portfolios.

HARROW, INC. Revenue and Earnings History — Quarterly Trend

In TTM 2026, HARROW, INC. reported revenue of $232M and earnings per share (EPS) of $-0.14. Net income for the quarter was $-16M. Gross margin was 73.2%. Operating income came in at $16M.

In FY 2025, HARROW, INC. reported revenue of $272M and earnings per share (EPS) of $-0.14. Net income for the quarter was $-5M. Gross margin was 75.0%. Revenue grew 36.4% year-over-year compared to FY 2024. Operating income came in at $31M.

In Q3 2025, HARROW, INC. reported revenue of $72M and earnings per share (EPS) of $0.03. Net income for the quarter was $1M. Gross margin was 75.3%. Revenue grew 45.4% year-over-year compared to Q3 2024. Operating income came in at $15M.

In Q2 2025, HARROW, INC. reported revenue of $64M and earnings per share (EPS) of $0.14. Net income for the quarter was $5M. Gross margin was 74.5%. Revenue grew 30.2% year-over-year compared to Q2 2024. Operating income came in at $11M.

Over the past 8 quarters, HARROW, INC. has demonstrated a growth trajectory, with revenue expanding from $49M to $232M. Investors analyzing HROW stock should weigh these quarterly trends alongside the valuation and quality metrics discussed above.

HROW Dividend Yield and Income Analysis

HARROW, INC. (HROW) does not currently pay a dividend. This is common among smaller companies in the Pharmaceutical Products industry that prefer to reinvest cash flows into business expansion rather than returning capital to shareholders. Income-focused investors looking for Healthcare dividend stocks may want to explore other Healthcare stocks or use the stock screener to filter by dividend yield.

HROW Momentum and Technical Analysis Profile

HARROW, INC. (HROW) has a momentum factor score of 47/100, reflecting neutral trend characteristics. The stock is neither significantly outperforming nor underperforming the broader market on a momentum basis. The investment factor score is 23/100, which measures capital allocation efficiency and asset growth patterns. The short interest score of 46/100 reflects moderate short selling activity.

HROW vs Competitors — Healthcare Sector Ranking and Peer Comparison

Within the Healthcare sector, HARROW, INC. (HROW) ranks #507 out of 838 stocks based on the Blank Capital composite score. This places HROW in the lower half of all Healthcare stocks in our coverage universe. Key competitors and sector peers include ASTRAZENECA PLC (AZN) with a score of 61.4/100, Sol-Gel Technologies Ltd. (SLGL) with a score of 56.6/100, VIEMED HEALTHCARE, INC. (VMD) with a score of 53.4/100, Innoviva, Inc. (INVA) with a score of 52.7/100, and JOHNSON & JOHNSON (JNJ) with a score of 51.7/100.

Comparing HROW against the S&P 500 benchmark is also instructive for understanding relative performance. Investors can view the full HROW vs S&P 500 (SPY) comparison to assess how HARROW, INC. stacks up against the broader market across all factor dimensions.

HROW Next Earnings Date

No upcoming earnings date has been announced for HARROW, INC. (HROW) at this time. Check the earnings calendar for the latest scheduling updates across all stocks in our coverage universe.

Should You Buy HROW? — Investment Thesis Summary

The quantitative profile for HARROW, INC. suggests caution. High volatility (stability score 36/100) increases portfolio risk.

In summary, HARROW, INC. (HROW) earns a Reduce rating with a composite score of 44.1/100 as of April 2026. The rating is derived from the Blank Capital Research methodology, which combines six factor dimensions into a single quantitative ranking. Investors should consider these quantitative signals alongside their own fundamental research, risk tolerance, and investment time horizon before making buy or sell decisions on HROW stock.

Related Resources for HROW Investors

Explore more research and tools: HROW vs S&P 500 comparison, top Healthcare stocks, stock screener, our methodology, quality factor explained, value factor explained, momentum factor explained. Compare HROW head-to-head with peers: HROW vs AZN, HROW vs SLGL, HROW vs VMD.